Ardsley Advisory Partners’s TherapeuticsMD TXMD Stock Holding History

Ardsley Advisory Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,000	Closed	-$4.92M	–	157
2018 Q3	$4.92M	Buy	15,000 +1,000	+7%	+$306K	0.66%	43
2018 Q2	$4.37M	Sell	14,000 -9,500	-40%	-$2.9M	0.66%	50
2018 Q1	$5.72M	Buy	23,500 +2,500	+12%	+$701K	0.86%	41
2017 Q4	$6.34M	Buy	21,000 +20,500	+4,100%	+$5.71M	0.77%	35
2017 Q3	$132K	Buy	+500	New	+$145K	0.02%	126

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Ardsley Advisory Partners's TXMD Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 15,000 shares — an estimated $4.92M sold.

Ardsley Advisory Partners first reported a position in TXMD in Q3 2017 and held it in 5 quarters. The position peaked at $6.34M in Q4 2017. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Ardsley Advisory Partners reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 15,000 TherapeuticsMD shares in Q4 2018, an estimated $4.92M.
Ardsley Advisory Partners first reported a position in TherapeuticsMD in Q3 2017 and held it in 5 quarters.
Ardsley Advisory Partners's TherapeuticsMD position peaked at $6.34M in Q4 2017.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.